Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 108.58M P/E - EPS this Y 41.90% Ern Qtrly Grth -
Income -43.15M Forward P/E -1.77 EPS next Y 8.60% 50D Avg Chg -7.00%
Sales 10.74M PEG -0.16 EPS past 5Y - 200D Avg Chg -9.00%
Dividend N/A Price/Book 0.97 EPS next 5Y 13.00% 52W High Chg -53.00%
Recommedations 2.00 Quick Ratio 8.09 Shares Outstanding 58.56M 52W Low Chg 29.00%
Insider Own 9.19% ROA -26.52% Shares Float 49.41M Beta 1.21
Inst Own 71.61% ROE -49.27% Shares Shorted/Prior 99.41K/212.10K Price 2.00
Gross Margin - Profit Margin - Avg. Volume 498,080 Target Price -
Oper. Margin -3,573.65% Earnings Date Mar 7 Volume 336,694 Change 1.52%
About aTyr Pharma, Inc.

aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. The company is also developing ATYR2810, a fully humanized monoclonal antibody that is in preclinical development for the treatment of solid tumors. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. The company was incorporated in 2005 and is headquartered in San Diego, California.

aTyr Pharma, Inc. News
02/23/24 We Think aTyr Pharma (NASDAQ:LIFE) Can Afford To Drive Business Growth
02/21/24 aTyr Pharma Announces Expanded Access Program (EAP) for EFZO-FIT™ Clinical Trial Participants
02/03/24 After losing 23% in the past year, aTyr Pharma, Inc. (NASDAQ:LIFE) institutional owners must be relieved by the recent gain
01/29/24 aTyr Pharma to Present Posters Highlighting Importance of Neuropilin-2 in Immune Regulation at Keystone Symposia on Myeloid Cell Diversity
01/18/24 aTyr Pharma Announces Howard University President Emeritus Dr. Wayne A. I. Frederick as Advisor
11/13/23 aTyr Pharma's Market Cap Drops To US$66m Leaving Insiders With Losses
11/13/23 aTyr Pharma Presents Poster Demonstrating Preclinical Effects of Efzofitimod in Rheumatoid Arthritis and Rheumatoid Arthritis-Associated ILD at the ACR Convergence 2023
11/09/23 aTyr Pharma Announces Third Quarter 2023 Results and Provides Corporate Update
11/01/23 aTyr Pharma to Present at November Investor Conferences
10/31/23 aTyr Pharma Announces Dosing of First Patient in Phase 2 EFZO-CONNECT™ Study of Efzofitimod in Patients with SSc-ILD
08/30/23 Down -9.64% in 4 Weeks, Here's Why You Should You Buy the Dip in Atyr Pharma (LIFE)
08/30/23 We're Hopeful That aTyr Pharma (NASDAQ:LIFE) Will Use Its Cash Wisely
08/24/23 aTyr Pharma to Present at the H.C. Wainwright 25th Annual Global Investment Conference
08/09/23 Atyr Pharma (LIFE) Reports Q2 Loss, Lags Revenue Estimates
08/09/23 aTyr Pharma Announces Second Quarter 2023 Results and Provides Corporate Update
07/20/23 aTyr Pharma, Inc. (NASDAQ:LIFE) is a favorite amongst institutional investors who own 56%
06/28/23 7 Growth Stocks That AI Predicts Will Deliver Triple-Digit Returns in 2023
06/22/23 European Commission Grants Orphan Drug Designation for aTyr Pharma’s Efzofitimod for Treatment of Systemic Sclerosis
06/20/23 aTyr Pharma to Present on Lead Therapeutic Candidate Efzofitimod at the World Association for Sarcoidosis and Other Granulomatous Disorders (WASOG) Conference
06/09/23 aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
LIFE Chatroom

User Image UniversalGonk Posted - 2 days ago

$LIFE i like the peace and quiet. The info you get here is mostly accurate. But unfortunately the 💎👐 types come with the volume so we'll need them.

User Image iBoughtTheWrongTicker Posted - 2 days ago

$LIFE this board needs more watchers. It’s a ghost town over here.

User Image Capitulation_0 Posted - 2 days ago

$LIFE story here has yet to be told. retail has no clue.

User Image Capitulation_0 Posted - 2 days ago

$LIFE I'm sticking to my flawed and 'likely' wrong theory that MM's are keeping the stock below $2 so that their 'friends' can load up here.

User Image Capitulation_0 Posted - 2 days ago

$LIFE It's official, HCW upgrade isn't worth a damn.

User Image Capitulation_0 Posted - 2 days ago

$LIFE Feels like when I was loaded up in IMCR in the low 40's..

User Image Capitulation_0 Posted - 3 days ago

$LIFE $1.89, $1.90 is its happy place

User Image iBoughtTheWrongTicker Posted - 3 days ago

$LIFE curlin

User Image Capitulation_0 Posted - 3 days ago

$LIFE I think EAP has been overlooked here...

User Image Capitulation_0 Posted - 3 days ago

$LIFE Erik Otto has some nice information on EAP https://twitter.com/ErikOtto2/status/1760715921331769408

User Image RallyRaider Posted - 3 days ago

$LIFE now do some serious damage off this trendline

User Image Drerekcohert90 Posted - 3 days ago

$LIFE $AKBA $ICU $CVKD Great picks Jack!

User Image jacksparo Posted - 3 days ago

$LIFE $CVKD $ICU $AKBA Under my minute vs minute chart 📊 indicators watch today for a possible update later ✅! Those stocks are in a very important level ! For ICU holding above 1.15 is essential to keep the bullish momentum and a lot still waiting also for any possible news soon 🔜! For LIFE a very important break up resistance test ✅! AKBA will have a test today also ✅! I will keep you posted team 📈💲📈!

User Image perchedcats Posted - 4 days ago

$LIFE increased my position by 50% during the run up from $1.30s. Top three position for me. High risk, high reward. Hopefully SP will continue to rise as we approach ph2 and ph3 readouts (Q4, and Q1 2025?).

User Image neverbeenwrong Posted - 4 days ago

$SYRA I entered here today. I see a young @jacksparo is also fond of this stock. Great minds think alike. $ATER $LIFE $TSLA

User Image UniversalGonk Posted - 4 days ago

$LIFE 20 Day SMA crossing up above the 200 Day SMA. Looks ready to resume the prior upward trend.

User Image neverbeenwrong Posted - 4 days ago

$LIFE Been in this stock for over a year. 13,000 shares. See you at $30.

User Image Capitulation_0 Posted - 4 days ago

$LIFE Oppenheimer ( was $17 but removed it) , RBC ($19), Piper ( $20) and MKM ($9) All early to mid 2023, except for HCW reiterating $35 today.

User Image Capitulation_0 Posted - 4 days ago

$LIFE The news is bullish...I read the PR as: there's no viable treatment and patients are pushing to continue on with therapy. FDA agrees.

User Image Stocks4thought Posted - 4 days ago

$LIFE BUY 2:56:28 $ 1.90 50,000

User Image Stocks4thought Posted - 4 days ago

$LIFE 2.12 and she blows thru the toll booth..............Wainright better be right $35--------------what smoke are they on? I'll take $6 again!!

User Image Capitulation_0 Posted - 4 days ago

$LIFE I mean.. I know HCW has some lofty targets and their upgrades really don't move the needle for the most part but this is one of the disjointed upgrade target and current price. 11:16 AM EST, February 21, 2024 (Benzinga Newswire) HC Wainwright & Co. analyst Joseph Pantginis reiterates aTyr Pharma (NASDAQ:LIFE) with a Buy and maintains $35 price target.

User Image Ninja_Tradez Posted - 4 days ago

📢 $LIFE - HC Wainwright & Co. Reiterates Buy on aTyr Pharma, Maintains $35 Price Target https://newsfilter.io/a/5d52e9e68741a2d07740baad015e80c5

User Image Stocks4thought Posted - 4 days ago

$LIFE Is there a READ THRU here- if their going EAP then from an investigator and sponsor perspective (FDA including) value'/efficacy are understood. Steroid use (taper most important) Company initiating program based on blinded EFZO-FIT™ study investigator and patient participant feedback.

User Image 45IQ Posted - 4 days ago

$LIFE The EAP program is YUGE. As far as SP goes, time will tell, but for me it looks as if patients that have completed the trial or didn't fit the criteria didn't have any other treatment options available that actually worked. Absolutely YUUUGE.

User Image iBoughtTheWrongTicker Posted - 4 days ago

$LIFE showing signs of life!!!

User Image Capitulation_0 Posted - 4 days ago

$LIFE Drives home the point that continuous steroid usage has serious side effects..

User Image Capitulation_0 Posted - 4 days ago

$LIFE "“compassionate use”, expanded access is a potential pathway for a patient with a serious or immediately life-threatening disease or condition to gain access to an investigational medical product (drug, biologic, or medical device) for treatment outside of clinical trials when no comparable..." To authorize the expanded access use, FDA must also determine (1) that the patient has a serious or life-threatening disease or condition and has no other comparable or satisfactory therapeutic options (§ 312.305(a)(1)); (2) that providing expanded access will not interfere with development of the drug for the expanded ...

User Image Capitulation_0 Posted - 4 days ago

$LIFE This 'compassionate' use might not get a lot of traction but it's very positive imo. It means that the study participants are willing to continue the therapy because it's effective and safe.

User Image Capitulation_0 Posted - 4 days ago

$LIFE This is a sign that the therapy works and is safe, again, low bar for success: "We are pleased to make efzofitimod available to patients beyond the duration of the EFZO-FIT™ clinical trial through this Individual Patient EAP,” said Sanjay S. Shukla , M.D., M.S., President and Chief Executive Officer of aTyr. “Based on interest from Principal Investigators (PIs) and patients who have or are in the process of completing the EFZO-FIT™ study, we have decided to implement this program in part to continue to support those patients who have dedicated their time and entrusted us with their health by participating in this important study. This program reflects our ongoing commitment to the sarcoidosis community as we work to develop a safe and effective treatment for a condition that has a high unmet medical need.”

Analyst Ratings
HC Wainwright & Co. Buy Feb 21, 24
HC Wainwright & Co. Buy Sep 21, 23
HC Wainwright & Co. Buy Sep 14, 23
HC Wainwright & Co. Buy Aug 10, 23
Piper Sandler Overweight Jul 21, 23
Oppenheimer Perform Jul 5, 23
HC Wainwright & Co. Buy May 23, 23
RBC Capital Outperform May 10, 23
Piper Sandler Overweight Apr 11, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Broadfoot Jill Marie Chief Financial Offi.. Chief Financial Officer Feb 05 Sell 1.69 1,590 2,687 20,821 02/06/24
SCHIMMEL PAUL Director Director May 10 Buy 2.25 200,000 450,000 313,023 05/11/23
Broadfoot Jill Marie Chief Financial Offi.. Chief Financial Officer Feb 03 Sell 2.36 1,566 3,696 15,460 02/06/23
Shukla Sanjay President and CEO President and CEO Nov 21 Buy 2.1405 10,000 21,405 50,798 11/21/22
Broadfoot Jill Marie Chief Financial Offi.. Chief Financial Officer Jan 13 Buy 6.75 1,923 12,980 12,112 01/18/22
Shukla Sanjay President and CEO President and CEO Jan 07 Buy 6.7613 5,000 33,806 25,798 01/10/22